“We are pleased with our results through the first nine months of the fiscal year,” said Dan Carestio, President and CEO of STERIS. “We are updating our outlook primarily to reflect a ...

The jury trial ended in a mistrial, which could potentially be favorable for STERIS as it allows them to prepare for and possibly achieve a more favorable outcome in a retrial. Isomedix intends to ...